An interventional study of Pomegranate Peel Extract Gel and Placebo gel in Periodontitis, sponsored by gehad samy. Recruiting at 1 site in Egypt. Open to participants aged 30 Years to 60 Years. Per ClinicalTrials.gov, last updated 2026-07-24.
Sponsored by gehad samy · Not applicable, Interventional, and Treatment
Among 119 studies in Periodontitis with a site in Egypt — 28 open to participants now, 37 under way, 3 of them phase 3. Periodontitis · Egypt.
Among the 119 studies in Periodontitis with a site in Egypt, this one is the 47th largest by planned enrollment of the 101 interventional ones that give a count, is one of 11 that started in 2026, is one of 61 with no phase, reaches primary completion later than 31 of the 36 other live ones, and was the 109th registered.
1,232 studies on the registry are indexed under Periodontitis; 295 are open to participants now.
Browse Periodontitis studies →28 of the 119 studies in Periodontitis with a site in Egypt are open now. Recruiting first, the newest first:
October 6 University · Sites in Egypt
Ages 25–45
Doaa Atta Aid · Sites in Egypt
Cairo University · Sites in Egypt
Ages 18+
Mansoura University · Sites in Egypt
Ages 20–40 · Healthy volunteers
husain abduljalil alam · Sites in Egypt
Ages 25–45 · Healthy volunteers
A study can be open while its sites in Egypt have not opened yet or have stopped. Only those recruiting at a site in Egypt →
Of the 158 Periodontitis studies recruiting now, 78 (49%) set no upper age limit and 60 (38%) stop at 75 or younger; 12 take children under 18; 76 take healthy volunteers.
This study: 30 Years to 60 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
119 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 21 · Phase 2 16 · Phase 3 7 · Phase 4 5
First in 2014; this study’s year is marked. 11 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 32 is below the median of 44 across 847 interventional studies indexed under Periodontitis.
Median enrollment 30 across the 101 interventional studies, 71 across the 18 observational. Of the 70 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
None of the 119 has an industry lead sponsor. The 10 most frequent:
This is the only study on the registry with gehad samy as lead sponsor.
gehad samy has 1 study filed under Periodontitis — fewer than ten, so there is no comparison to draw.
8 of the studies in Periodontitis with a site in Egypt that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07368699Alexandria UniversityActive Oxygen Releasing Gel With Photodynamic Therapy in Treating Stage III Periodontitis | 2026-12 |
| NCT07731113Cairo UniversityEvaluation of Hyaluronic Acid and Chlorhexidine Gel as an Adjunct to Minimally Invasive Non-surgical Therapy in the Treatment of Stage III and IV Periodontitis | 2026-12-10 |
| NCT07725393gehad samyAdjunctive Subgingival Pomegranate Peel Extract Gel for Stage II-III Periodontitis | 2027-01 |
| NCT07599657Cairo UniversitySurfactant Protein D Levels in GCF Before and After MINST in Periodontitis | 2027-02-01 |
| NCT07928752Badr UniversityEffects of Adjunctive Melatonin Gel in Type II Diabetics With Stage III-IV Periodontitis | 2027-03 |
Add all 8 to your calendar (.ics) → With an account.
Among the 119 studies in Periodontitis with a site in Egypt, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This randomized, triple-blind, placebo-controlled split-mouth clinical trial aims to evaluate the clinical and biochemical efficacy of subgingival pomegranate peel extract gel as an adjunct to scaling and root planing (SRP) in the treatment of Stage II-III periodontitis.
Thirty-two participants diagnosed with Stage II-III periodontitis will receive SRP in all selected periodontal sites. Test sites will receive locally delivered pomegranate peel extract gel, while contralateral control sites will receive a placebo gel. Clinical periodontal parameters, including probing pocket depth (PPD), clinical attachment level (CAL), plaque index (PI), gingival index (GI), bleeding on probing (BOP), and gingival crevicular fluid levels of matrix metalloproteinase-8 (MMP-8), will be assessed at baseline, 1 month, 3 months, and 6 months to evaluate whether adjunctive pomegranate peel extract gel improves periodontal healing compared with SRP alone.
Clinical outcomes including probing pocket depth (PPD), clinical attachment level (CAL), plaque index (PI), gingival index (GI), and bleeding on probing (BOP) will be recorded at baseline, 1 month, 3 months, and 6 months. Gingival crevicular fluid samples will also be collected at the same time points for quantitative measurement of matrix metalloproteinase-8 (MMP-8) using enzyme-linked immunosorbent assay (ELISA).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Periodontal sites receive scaling and root planing followed by subgingival application of pomegranate peel extract gel.
Drug: Pomegranate Peel Extract Gel
Periodontal sites receive scaling and root planing followed by subgingival application of placebo gel with identical appearance and consistency.
Other: Placebo gel
Locally delivered subgingival gel containing pomegranate peel extract administered after scaling and root planing.
Placebo gel without active ingredient, identical in appearance and consistency to the experimental gel, administered after scaling and root planing.
Change in Probing Pocket Depth (PPD)
Change in probing pocket depth (PPD), measured in millimeters using a calibrated periodontal probe at the selected periodontal sites.
Time frame: Baseline, 1 month, 3 months, and 6 months
Change in Clinical Attachment Level (CAL)
Change in clinical attachment level (CAL), measured in millimeters using a calibrated periodontal probe at the selected periodontal sites.
Time frame: Baseline, 1 month, 3 months, and 6 months
Change in Plaque Index (PI)
Change in plaque index (PI) assessed using the Silness and Löe Plaque Index.
Time frame: Baseline, 1 month, 3 months, and 6 months
Change in Gingival Index (GI)
Change in gingival index (GI) assessed using the Löe and Silness Gingival Index.
Time frame: Baseline, 1 month, 3 months, and 6 months
Change in Bleeding on Probing (BOP)
Change in bleeding on probing (BOP), assessed as the presence or absence of bleeding following gentle periodontal probing.
Time frame: Baseline, 1 month, 3 months, and 6 months
Change in Gingival Crevicular Fluid Matrix Metalloproteinase-8 (MMP-8) Levels
Change in gingival crevicular fluid matrix metalloproteinase-8 (MMP-8) concentration measured using enzyme-linked immunosorbent assay (ELISA).
Time frame: Baseline, 1 month, 3 months, and 6 months
Plan to share: No
Started Jul 2026 (actual). Primary completion is estimated for Jan 2027, 6 months after the start.
Of 481 non-industry interventional studies with no phase under Periodontitis, half reached primary completion within 15 months of starting (the median), counting those still running; a quarter within 8 and three quarters within 31. This study's planned 6 months is below that.
Counting every sponsor, half of 495 studies reached it within 15 months; a quarter within 8 and three quarters within 31.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.